AOCNP study plan

Diagram the hallmarks of cancer and annotate how each hallmark maps to a therapeutic target class

Sequence the phases of the cell cycle and label the checkpoints, cyclins, and cyclin-dependent kinases that govern each transition

Contrast proto-oncogenes, oncogenes, and tumor suppressor genes, generating three named clinical examples of each

Outline the multistep model of carcinogenesis from initiation through promotion and progression, including the role of DNA repair defects

Interpret serum tumor markers and explain why each is used for monitoring rather than screening

Classify cytotoxic agents by mechanism of action and cell-cycle specificity without reference notes

Build a toxicity profile for each major drug class linking mechanism to expected adverse effect

Explain the four R's of radiobiology and distinguish external beam, brachytherapy, and systemic radiotherapy

Describe the signaling pathways targeted by small-molecule inhibitors and monoclonal antibodies

Predict which patients are candidates for a given targeted agent based on molecular findings

Apply age- and risk-based screening recommendations to simulated patients across breast, colorectal, cervical, lung, and prostate cancer

Calculate and interpret sensitivity, specificity, positive predictive value, and negative predictive value from a 2x2 table

Assign TNM stage from a clinical vignette and state the corresponding stage group

Identify red flags for hereditary cancer syndromes and state the criteria that trigger genetic referral

Differentiate diagnostic, predictive, and prognostic biomarkers with a clinical example of each

Distinguish the mechanisms of checkpoint inhibitors, CAR-T therapy, and bispecific antibodies, and outline immune-related adverse event management

Order multimodal treatment options for three common solid tumors and justify the sequence

Describe clinical trial phases, endpoints, and response criteria used to interpret published results

Compare autologous and allogeneic transplant indications, conditioning regimens, and major risks

Grade and manage common treatment toxicities using standardized grading criteria

Select and combine antiemetic regimens by emetogenic risk level and patient-specific factors

Recognize and triage neutropenic fever, tumor lysis syndrome, spinal cord compression, superior vena cava syndrome, and hypercalcemia of malignancy

Construct an analgesic plan using the WHO ladder and perform an equianalgesic opioid conversion

Screen for and stage psychosocial distress, depression, and caregiver burden using validated tools

Conduct a structured goals-of-care and code status conversation using a defined communication framework

Assemble the required elements of a survivorship care plan including surveillance schedule, late-effect risks, and health promotion

Identify secondary malignancy and cardiotoxicity risk by prior treatment exposure and set an appropriate screening interval

Apply fertility preservation and rehabilitation referral criteria at the point of diagnosis and after treatment

Screen for financial toxicity, insurance barriers, and medication adherence risk with actionable interventions

Coordinate handoff between oncology, primary care, and specialty services using a structured transition summary

Complete a full-length timed practice examination under test-day conditions

Categorize every incorrect item by domain and by error type (knowledge gap, misread, or reasoning error)

Re-teach the three weakest content areas using spaced repetition across at least three sessions

Convert high-yield facts into flashcards and review them to a 90% recall threshold

Re-attempt every previously missed item and explain the correct rationale aloud without notes

Run three timed 25-item domain-specific drills targeting the weakest areas

Synthesize cross-domain content into a single condensed review sheet

Rehearse test-day logistics, pacing strategy, and anxiety management plan